Medtronic (MDT) has recently applied for approval from the U.S. Food and Drug Administration (FDA) for its latest insulin pump technology. The applications include two distinct products: the MiniMed 780G pump, designed as an alternate controller enabled insulin pump, and the SmartGuard algorithm, intended for use as an automated glycemic controller. These are submitted under the 510(k) premarket notification process.
Gaining FDA clearance would allow Medtronic to integrate these products with a continuous glucose monitoring (CGM) system supplied by Abbott (ABT, Financial), connected through Abbott’s cutting-edge CGM platform. This follows an agreement announced in August where the two companies decided to collaborate on an advanced diabetes management system.
Under this collaboration, Abbott will provide the CGM devices, which are compatible only with Medtronic’s smart dosing devices and software. These systems, featuring automated insulin delivery and smart multiple daily injection functionalities, will be distributed exclusively through Medtronic.
